Human IGF-II R/IGF2R Antibody

Catalog #: MAB24471
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB24471
MAB24471-SP

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IGF-II R/IGF2R Antibody Summary

Species Reactivity

Human

Specificity

Detects human IGF-II R/IGF2R in ELISAs.

Source

Monoclonal Mouse IgG_2B Clone # 372616

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGF-II R/IGF2R
Ser1510-Phe2108
Accession # P11717

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Human IGF-II R/IGF2R Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human IGF-II R/IGF2R Biotinylated Antibody (Catalog # BAF2447)

Standard: Recombinant Human IGF-II R/IGF2R Protein, CF (Catalog # 2447-GR)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGF-II R/IGF2R

The type 2 insulin-like growth factor receptor (also known as cation-independent mannose-6 phosphate receptor/CI-MPR) is a 300 kDa member of the P-type lectin family of molecules. P-type lectins generate functional eukaryotic lysosomes by binding and sorting lysosomal enzymes expressing phosphorylated mannose residues (M6P) (1-3). IGF-II R is a type I transmembrane glycoprotein that contains a 2,264 amino acid (aa) extracellular region, a 23 aa transmembrane segment and a 124 aa cytoplasmic tail (4, 5). The extracellular region consists of 15 contiguous "binding" repeats of about 150 aa each. The odd-numbered repeats interact with "ligands" while the even-numbered repeats likely generate a nondisulfide homodimer in the membrane (1). Repeat #11 binds IGF-II, while repeats 3 and 9 bind mannose-6 phosphate; repeat #13 contains a fibronectin type II motif and assists in IGF-II binding (1, 2). In the extracellular region of IGF-II R expressed by R&D Systems (600 aa), human IGF-II R is 85% aa identical to both mouse and bovine IGF-II R. This expressed region includes binding repeats #11, 12, and 13. In addition to IGF-II, CI-MPR/IGF-II R binds non-M6P containing ligands such as retinoic acid, urokinase-type plasminogen-activator receptor and plasminogen, plus M6P-containing molecules such as lysosomal enzymes, TGF-beta 1 precursor, proliferin, LIF, CD26, herpes simplex glycoprotein D and granzymes A and B (2, 6). IGF-II R regulates many diverse biological functions that range from intracellular trafficking to the internalization of extracellular factors and modulation of cellular responses. It delivers newly synthesized M6P-tagged lysosomal enzymes from the trans-golgi network to endosomes, and facilitates the clearance of extracellular lysosomal and matrix degrading enzymes by internalization into clathrin-coated vesicles and delivery into endosomes. With respect to IGF-II biology, it would appear that IGF-II R is principally a regulator of local IGF-II levels, targeting IGF-II for destruction in lysosomes (2). However, some evidence suggests the receptor will signal via G‑proteins, an effect that has yet to be conclusively shown (6).

References

Ghosh, P. et al. (2003) Nat. Rev. Mol. Cell. Biol. 4:202.
Dahms, N.M. and M.K. Hancock (2002) Biochim. Biophys. Acta. 1572:317.
Zaina, S. and J. Nilsson (2003) Curr. Opin. Lipidol. 14:483.
Morgan, D.O. et al. (1987) Nature 329:301.
Oshima, A. et al. (1988) J. Biol. Chem. 263:2553.
Hawkes, C. and S. Kar (2004) Brain Res. Rev. 44:117.

Long Name

Insulin-like Growth Factor II Receptor

Entrez Gene IDs

3482 (Human)

Alternate Names

300 kDa mannose 6-phosphate receptor; cation-independent mannose-6 phosphate receptor; cation-independent mannose-6-phosphate receptor; CD222 antigen; CD222; CI Man-6-P receptor; CIMPR; CI-MPR; IGF2R; IGF-II R; IGF-II receptor; IGFIIR; IGF-IIR; insulin-like growth factor 2 receptorM6P/IGF2R; Insulin-like growth factor II receptor; M6P/IGF2 receptor; M6PR; M6P-R; MPR 300; MPR1; MPRI; MPRIM6PR

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citation for Human IGF-II R/IGF2R Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

CD44(+) fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling
Authors: Y Liu, C Yu, Y Wu, X Sun, Q Su, C You, H Xin
J. Cell. Mol. Med., 2017-05-18;0(0):.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Capture)